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Introduction {#jdi13088-sec-0001}
============

Although metformin is recommended as first‐line therapy in the American Diabetes Association/European Association for the Study of Diabetes consensus recommendations, ∼40% of patients initiating oral antidiabetic drugs (OADs) have been reported to have not received this recommended initial therapy[1](#jdi13088-bib-0001){ref-type="ref"}, [2](#jdi13088-bib-0002){ref-type="ref"}, [3](#jdi13088-bib-0003){ref-type="ref"}. Furthermore, the applicability of these recommendations to Asians, including the Japanese, has not been clarified. Compared with Caucasians, type 2 diabetes mellitus in Asians tends to be characterized more by impaired insulin secretion than by increased insulin resistance. Therefore, the choice of OADs depends on patient factors, such as age, complications and risk of hypoglycemia, while considering the characteristics and side‐effects of each drug[4](#jdi13088-bib-0004){ref-type="ref"}, [5](#jdi13088-bib-0005){ref-type="ref"}.

According to a study that investigated the prescription trend of initial OADs selection for type 2 diabetes mellitus patients in Japan, dipeptidyl peptidase‐4 inhibitors (DPP‐4I) were the most preferred first‐line OADs, followed by metformin[6](#jdi13088-bib-0006){ref-type="ref"}. When selecting a hypoglycemic agent, not only medical outcomes, but also patients' quality of life and attitude toward treatment, should be considered. The frequency of treatment intensification affects the quality of life of type 2 diabetes mellitus patients. Therefore, it is important for the initial OADs not only to have good glycemic control impact, but also to allow patients to continue the initial treatment. In the present study, we investigated the frequency of occurrence to treatment intensification and the effect of blood glucose control at the end of a 2‐year observation in treatment‐naïve patients who were first treated with metformin or DPP‐4I.

Methods {#jdi13088-sec-0002}
=======

A retrospective cohort study was carried out at Tokyo Saiseikai Central Hospital in Tokyo, Japan. We included patients who newly initiated either metformin or DPP‐4I between January 2009 and March 2015. The exclusion criteria were: (i) type 1 diabetes; (ii) age \<18 years; (iii) an estimated glomerular filtration rate \<30 mL/min/1.73 m^2^; and (iv) a follow‐up period \<2 years. We reviewed medical records to retrieve the patients' clinical information.

The primary outcome was the frequency of occurrence to treatment intensification, defined as initiating or adding another class of OADs (include glucagon‐like peptide 1 agonists) or insulin. The secondary outcome was hemoglobin A1c (HbA1c) levels after a 2‐years observation period.

Normally distributed numerical data are presented as the mean ± standard deviation. Categorical variables were analyzed using Fisher\'s exact test and the χ^2^‐test, and are expressed as absolute numbers or percentages. Continuous variables were analyzed using an unpaired Student\'s *t*‐test. To evaluate the association of the frequency of occurrence to treatment intensification, Kaplan--Meier statistics were used and assessed using the Cox regression analysis, which was adjusted for age, sex, estimated glomerular filtration rate, body mass index and baseline HbA1c, and expressed as a hazard ratio and 95% confidence interval. We used patient characteristics at baseline as the predictor variables in univariate analysis, carried out multivariate analysis using factors found to be *P* \< 0.2 and calculated the odds ratio.

Differences were regarded as significant when *P* \< 0.05. All statistical analyses were carried out using the Stata software (version 10; StataCorp, College Station, TX, USA). The present study was carried out in accordance with ethical guidelines for medical and health research involving human participants. The ethics board of the Tokyo Saiseikai Central Hospital approved the study (control number: 27--11).

Results {#jdi13088-sec-0003}
=======

The 930 patients who met the inclusion criteria (Table [1](#jdi13088-tbl-0001){ref-type="table"}) consisted of 624 (67.0%) and 306 patients (33.0%) who initiated metformin and DPP‐4I, respectively. Compared with initiation of DPP‐4I, patients who initiated metformin were younger, more likely to be obese and less likely to have chronic kidney disease.

###### 

Patient characteristics

                              Mean ± SD or *n* (%)   *P* (metformin vs DPP‐4I)                 
  --------------------------- ---------------------- --------------------------- ------------- ---------
  Male, *n* (%)               711 (76.5)             411 (76.7)                  233 (76.1)    0.877
  Age (years)                 60.1 ± 11.3            58.1 ± 10.6                 64.5 ± 11.5   
  \<65, *n* (%)               310 (33.3)             157 (25.2)                  153 (50.0)    \<0.001
  65≤, *n* (%)                620 (66.7)             467 (74.8)                  153 (50.0)    
  HbA1c (%)                   7.9 ± 2.0              7.9 ± 2.0                   8.0 ± 1.9     
  \<7.0, *n* (%)              177 (19.0)             120 (19.2)                  57 (18.6)     0.384
  7.0 to \<8.0, *n* (%)       372 (40.0)             247 (39.6)                  125 (40.9)    
  8.0, *n* (%)                381 (41.0)             257 (41.2)                  124 (40.5)    
  BMI (kg/m^2^)               25.1 ± 8.7             25.8 ± 9.9                  23.5 ± 4.2    
  \<25, *n* (%)               564 (60.6)             336 (53.8)                  228 (74.5)    0.004
  25≤, *n* (%)                366 (39.4)             288 (46.2)                  78 (25.5)     
  eGFR (mL/min/1.73 m^2^)     73.3 ± 16.9            75.1 ± 15.6                 69.7 ± 18.6   
  \<60, *n* (%)               177 (19.0)             91 (14.6)                   86 (28.1)     \<0.001
  60≤, *n* (%)                753 (81.0)             533 (85.4)                  220 (71.9)    
  Diabetes duration (years)   4.9 ± 5.9              5.0 ± 5.8                   4.7 ± 6.3     0.461

Data are presented as the mean ± standard deviation. BMI, body mass index; eGFR, estimated glomerular filtration rate; HbA1c, hemoglobin A1c; SD, standard deviation.
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Treatment intensification {#jdi13088-sec-0004}
-------------------------

Compared with the initial period of 12 months, the rate of treatment intensification in the latter 12 months was significantly higher for both metformin (initial 12 months vs latter 12 months: 20.4% vs 56.7%, *P* \< 0.001) and DPP‐4 (initial 12 months vs latter 12 months: 18.0% vs 37.8%, *P* \< 0.001). These results were also significant in the multivariable Cox proportional hazards models: HbA1c value of 7.0% to \<8.0%, \>8.0% and initiation of DPP‐4I (Figure [1](#jdi13088-fig-0001){ref-type="fig"}). The transition of HbA1c between 6 and 12 months after the start of observation (6 months, 12 months, 18 months, 24 months) was 6.91 ± 0.78, 7.02 ± 1.01, 6.92 ± 0.74 and 7.06 ± 0.88 for DPP‐4I, and 7.29 ± 0.93, 7.34 ± 0.97, 7.30 ± 0.93 and 7.42 ± 0.97 for metformin, respectively. The results of the multivariate analysis adjusted (Table [2](#jdi13088-tbl-0002){ref-type="table"}) showed that the following were statistically significant: HbA1c value of 7.0 to \<8.0%, \>8.0%, body mass index ≥25 (kg/m^2^) and initiation of DPP‐4I.

![Rates of treatment intensification were significantly lower for dipeptidyl peptidase‐4 inhibitor (DPP‐4I; 31.0%) than for metformin (45.2%), respectively (log--rank test, *P*  \< 0 .001). Statistical comparison of treatment intensification during 24 months in patients with type 2 diabetes mellitus with the initiation of metformin or DPP‐4I treatment is shown in the inserted table. Hazard ratio is the Cox proportional hazards model adjusted by sex, age, hemoglobin A1c (HbA1c), body mass index (BMI) and estimated glomerular filtration rate (eGFR). CI, confidence interval.](JDI-11-96-g001){#jdi13088-fig-0001}

###### 

Logistic regression model for factors related to the achievement of hemoglobin A1c value of \<7.0% at the end of the 2‐year of follow‐up observation period at baseline characteristics

                                       Multivariate analysis                
  ------------------------------------ ----------------------- ------------ ---------
  Age (years)                                                               
  \<65                                 Reference               --           --
  65                                   1.35                    0.97--1.88   0.083
  HbA1c at baseline (%)                                                     
  \<7.0                                Reference               --           --
  7.0 to \<8.0                         0.32                    0.21--0.49   \<0.001
  8.0                                  0.27                    0.17--0.41   \<0.001
  BMI (kg/m^2^)                                                             
  \<25                                 Reference               --           --
  25                                   0.64                    0.47--0.87   0.005
  eGFR (mL/min/1.73 m^2^)                                                   
  \<60                                 Reference               --           --
  60                                   0.96                    0.65--1.42   0.842
  Initiating oral antidiabetic drugs                                        
  Metformin                            Reference               --           --
  DPP‐4I                               1.94                    1.39--2.72   \<0.001

Adjusted Age, hemoglobin A1c (HbA1c) at baseline, body mass index (BMI), estimated glomerular filtration rate (eGFR), initiating oral antidiabetic drugs. CI, confidence interval; DPP‐4I, dipeptidyl peptidase‐4 inhibitors.
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Discussion {#jdi13088-sec-0005}
==========

We showed that patients initially prescribed DPP‐4I were significantly less likely to require treatment intensification than those prescribed metformin. These observations for DPP‐4I were presumed to be attributable to less frequent administration, similar impact on weight gain[7](#jdi13088-bib-0007){ref-type="ref"}, [8](#jdi13088-bib-0008){ref-type="ref"}, [9](#jdi13088-bib-0009){ref-type="ref"}, [10](#jdi13088-bib-0010){ref-type="ref"}, [11](#jdi13088-bib-0011){ref-type="ref"}, [12](#jdi13088-bib-0012){ref-type="ref"}, [13](#jdi13088-bib-0013){ref-type="ref"} and enhanced tolerance compared with metformin[14](#jdi13088-bib-0014){ref-type="ref"}, [15](#jdi13088-bib-0015){ref-type="ref"}. Treatment intensification could be undesirable to patients[16](#jdi13088-bib-0016){ref-type="ref"}, [17](#jdi13088-bib-0017){ref-type="ref"}, [18](#jdi13088-bib-0018){ref-type="ref"}, and inherently associated with increased adverse effects, costs and complexity of medical treatment.

The present study showed that DPP‐4I displayed an advantage in achieving an HbA1c value \<7.0% compared with metformin. A previous study has reported that DPP‐4Is were associated with a smaller decline in HbA1c and a lower chance of reaching the HbA1c goal of \<7% than metformin, suggesting the inferiority of DPP‐4I to metformin as monotherapy[19](#jdi13088-bib-0019){ref-type="ref"}. However, previous studies have suggested that incretin‐based therapies, such as DPP‐4I, were more effective in Asian patients than they were in Caucasian patients[20](#jdi13088-bib-0020){ref-type="ref"}, [21](#jdi13088-bib-0021){ref-type="ref"}, [22](#jdi13088-bib-0022){ref-type="ref"}, [23](#jdi13088-bib-0023){ref-type="ref"}, [24](#jdi13088-bib-0024){ref-type="ref"}. Furthermore, a cohort study in Japan has shown that the glucose‐lowering effects of DPP‐4I and metformin are similar[25](#jdi13088-bib-0025){ref-type="ref"}. However, in patients with a high value of HbA1c (approximately 8%), DPP‐4I is more effective compared with metformin at the onset of OAD[25](#jdi13088-bib-0025){ref-type="ref"}. In the present study, DPP‐4I had a higher odds ratio for achieving HbA1c \>7% than metformin did, because the baseline HbA1c was relatively high, at approximately 8%. DPP‐4I was superior to metformin in lowering HbA1c, which could translate into reduced need for treatment intensification. Furthermore, transition of HbA1c tended to rise from 6 to 12 months in the case of both metformin and DPP‐4I. The HbA1c in DPP‐4I tended to be closer to the target value of Japan\'s glycemic control of 7.0%, whereas HbA1c transitioned at approximately 7.3% in the case of metformin at 6 months or later. For these reasons, the rate of achieving the HbA1c target with metformin is estimated to be low compared with DPP‐4I. Therefore, it can be considered that the rate of treatment intensification was high at 12 months or later.

The present study had some limitations that are worth mentioning. First, the decision to make treatment intensification from initial choice of OADs had no clear criteria and was at the discretion of the physician. Therefore, it could not be ruled out that the particular physician\'s treatment policy might have influenced the outcome. Second, the present study was retrospective; thus, we could not examine detailed reasons for the treatment intensification, such as lack of therapeutic effect, side‐effects and cost.

In conclusion, these findings showed that DPP‐4I was one of the preferred first‐line treatments in Japan because of a high rate of treatment continuation and superior HbA1c‐lowering effect. This information would provide guidance in selecting initial OADs to optimize type 2 diabetes mellitus management in Japan, as well as the rest of Asia. Maintaining initial treatment and achieving HbA1c targets might reduce the likelihood of diabetic complications and improve quality of life, so details need to be investigated.
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